High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.

[1]  H. Levin,et al.  External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. , 1997, The cancer journal from Scientific American.

[2]  E. Bergstralh,et al.  Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. , 2000, The Journal of urology.

[3]  A. Martinez,et al.  The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology. , 1998, International journal of radiation oncology, biology, physics.

[4]  F. Vicini,et al.  The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. , 1999, International journal of radiation oncology, biology, physics.

[5]  G Starkschall,et al.  Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Zelefsky,et al.  Histopathologic effects of three-dimensional conformal external beam radiation therapy on benign and malignant prostate tissues. , 1999, The American journal of surgical pathology.

[7]  M. Zelefsky,et al.  Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. , 1997, Urology.

[8]  C. Ling,et al.  The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma. , 1995, The cancer journal from Scientific American.

[9]  R. Weichselbaum,et al.  Caution in interpreting biochemical control rates after treatment of prostate cancer: length of follow-up influences results. , 1999, Urology.

[10]  C. Reddy,et al.  Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. , 2000, Urology.

[11]  William R. Fair,et al.  DOSE ESCALATION WITH THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY AFFECTS THE OUTCOME IN PROSTATE CANCER , 1998 .

[12]  C C Ling,et al.  Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  F. Vicini,et al.  The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma , 2000, Cancer.

[14]  T. Stamey,et al.  Biological determinants of cancer progression in men with prostate cancer. , 1999, JAMA.

[15]  James D. Cox,et al.  Consensus statement: Guidelines for PSA following radiation therapy , 1997 .

[16]  R Mohan,et al.  Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation. , 1996, International journal of radiation oncology, biology, physics.

[17]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[18]  A. Zietman,et al.  The durability of PSA failure-free survival from 5 years to 13 years following radiotherapy in patients with localized prostate cancer , 2000 .

[19]  M. Piérart,et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. , 1997, The New England journal of medicine.

[20]  A. D'Amico,et al.  Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml. , 1997, International journal of radiation oncology, biology, physics.

[21]  A Pollack,et al.  Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. , 2000, International journal of radiation oncology, biology, physics.

[22]  M. Zelefsky,et al.  Long term tolerance of high dose three‐dimensional conformal radiotherapy in patients with localized prostate carcinoma , 1999, Cancer.

[23]  G. Perry,et al.  Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma , 1997, Cancer.

[24]  Beahrs Oh,et al.  The American Joint Committee on Cancer. , 1984 .

[25]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[26]  G. Perry,et al.  Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. , 1995, Urology.

[27]  Myron Tanncnbaum,et al.  Urologic pathology: The prostate , 1977 .

[28]  G J Kutcher,et al.  Locally advanced prostatic cancer: long-term toxicity outcome after three-dimensional conformal radiation therapy--a dose-escalation study. , 1998, Radiology.

[29]  R Mohan,et al.  The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. , 1994, Seminars in oncology.

[30]  M. Kattan,et al.  The definition of biochemical failure in patients treated with definitive radiotherapy. , 2000, International journal of radiation oncology, biology, physics.

[31]  G E Hanks,et al.  The effect of dose on local control of prostate cancer. , 1988, International journal of radiation oncology, biology, physics.

[32]  M. Zelefsky,et al.  Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: interim report of a phase 1 dose-escalation study. , 1994, The Journal of urology.

[33]  M. Zelefsky,et al.  Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. , 1994, International journal of radiation oncology, biology, physics.

[34]  G J Kutcher,et al.  Three-dimensional conformal radiotherapy and dose escalation: where do we stand? , 1998, Seminars in radiation oncology.

[35]  R. Rhamy,et al.  Extended biopsy followup after full course radiation for resectable prostatic carcinoma. , 1975, The Journal of urology.

[36]  A. Fortin,et al.  Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[37]  D. Kuban,et al.  Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. , 1999, JAMA.

[38]  D. Hussey.  American Society for Therapeutic Radiology and Oncology , 2001 .

[39]  A. Hanlon,et al.  Dose selection for prostate cancer patients based on dose comparison and dose response studies. , 2000, International journal of radiation oncology, biology, physics.

[40]  W. van Putten,et al.  Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. , 1990, International journal of radiation oncology, biology, physics.

[41]  A. Pollack,et al.  External beam radiotherapy dose response of prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[42]  M. Kattan,et al.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.

[43]  I. Rosen,et al.  4 Preliminary results of a randomized dose-escalation study comparing 70 GY to 78 GY for the treatment of prostate cancer , 1999 .

[44]  P. Rubin,et al.  Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. , 1991, International journal of radiation oncology, biology, physics.

[45]  C. Ling,et al.  Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. , 2000, International journal of radiation oncology, biology, physics.

[46]  P. Walsh,et al.  Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis. , 1998, Urology.

[47]  D. Cox.  Regression Models and Life-Tables , 1972 .

[48]  A. Hanlon,et al.  Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness. American Society for Therapeutic Radiology and Oncology. , 2000, International journal of radiation oncology, biology, physics.

[49]  C. Iselin,et al.  Radical perineal prostatectomy: oncological outcome during a 20-year period. , 1999, The Journal of urology.

[50]  C. Ling,et al.  Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate. , 1997, International journal of radiation oncology, biology, physics.

[51]  P. Scardino,et al.  The prognostic significance of post-irradiation biopsy results in patients with prostatic cancer. , 1986, The Journal of urology.

[52]  D. Grignon,et al.  Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.